Panel Discussion

Segment 4: Technological Approaches to Abuse Deterrence
April 28, 2016 – 
In this segment, moderator J David Haddox, DDS, MD, and panelists Jeffrey Dunn, PharmD, MBA; Peggy Johnson; and Burton VanderLaan, MD, FACP, discuss various technological approaches to abuse deterrence.
Segment 3: Managed Care Perspectives on Abuse-Deterrent Formulations
April 28, 2016 – 
In this segment, moderator J David Haddox, DDS, MD, and panelists Jeffrey Dunn, PharmD, MBA; Peggy Johnson; and Burton VanderLaan, MD, FACP, discuss the role of abuse-deterrent formulations as one component of a multifaceted strategy to address nonmedical use of opioids.
Segment 2: Combating Opioid Abuse
April 28, 2016 – 
Collaboration among multiple stakeholders is needed to address the problem of nonmedical use of opioids, as discussed by moderator J David Haddox, DDS, MD, and panelists Jeffrey Dunn, PharmD, MBA; Peggy Johnson; and Burton VanderLaan, MD, FACP.
Segment 1: Nonmedical Use of Opioids: The Scope of the Problem
April 28, 2016 – 
In this segment, moderator J David Haddox, DDS, MD, vice president for health policy at Purdue, discusses the scope of the opioid problem with the panel, which consists of Jeffrey Dunn, PharmD, MBA, senior vice president and chief clinical officer at VRx Pharmacy Services; Peggy Johnson, current principal at MMJ Advisors and past chief pharmacy officer at Horizon Blue Cross and Blue Shield of New Jersey; and Burton VanderLaan, MD, FACP, medical director at Priority Health.
Segment 14: The Future of Clinical Pathways
April 27, 2016 – 
Panel participants provide their perspectives on how they would like to see the field of oncology clinical pathways develop.
Segment 13: Place for Palliative Care in Clinical Pathways
April 27, 2016 – 
Panelists explain the need and the challenges with including principles of palliative care in oncology clinical pathways.
Segment 12: Patient Awareness About Clinical Pathways
April 27, 2016 – 
Robert Dubois, MD, PhD, shares findings from their recently published study in The American Journal of Managed Care, which showed that patients do not know they are being treated on predetermined pathways.
Segment 11: Can Clinical Pathways Restrict Patient Access?
April 27, 2016 – 
Neither Blase Polite, MD, MPP, not Robert Dubois, MD, PhD, believe that clinical pathways restrict patient access to care.
Segment 10: Can Clinical Pathways Be Personalized?
April 27, 2016 – 
According to Blase Polite, MD, MPP, pathways are well-designed to allow personalized medicine.
Segment 9: Ease of Integrating Pathways Based on Site of Care
April 27, 2016 – 
According to Blase Polite, MD, MPP, it is much harder for a cancer center to adapt care pathways than it is for a smaller clinic.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!